Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial
We sought to assess the occurrence of events after blinded study drug discontinuation and transition to open-label vitamin K antagonist (VKA) in ARISTOTLE.
Gespeichert in:
| Autor*in: |
Granger, Christopher B. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2015 |
|---|
| Umfang: |
6 |
|---|
| Übergeordnetes Werk: |
Enthalten in: 625: Withdrawn - 2013, AHJ, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:169 ; year:2015 ; number:1 ; pages:25-30 ; extent:6 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.ahj.2014.09.006 |
|---|
| Katalog-ID: |
ELV023904658 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV023904658 | ||
| 003 | DE-627 | ||
| 005 | 20230623172015.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ahj.2014.09.006 |2 doi | |
| 028 | 5 | 2 | |a GBVA2015019000025.pica |
| 035 | |a (DE-627)ELV023904658 | ||
| 035 | |a (ELSEVIER)S0002-8703(14)00564-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 570 |q VZ |
| 084 | |a BIODIV |q DE-30 |2 fid | ||
| 100 | 1 | |a Granger, Christopher B. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial |
| 264 | 1 | |c 2015 | |
| 300 | |a 6 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a We sought to assess the occurrence of events after blinded study drug discontinuation and transition to open-label vitamin K antagonist (VKA) in ARISTOTLE. | ||
| 700 | 1 | |a Lopes, Renato D. |4 oth | |
| 700 | 1 | |a Hanna, Michael |4 oth | |
| 700 | 1 | |a Ansell, Jack |4 oth | |
| 700 | 1 | |a Hylek, Elaine M. |4 oth | |
| 700 | 1 | |a Alexander, John H. |4 oth | |
| 700 | 1 | |a Thomas, Laine |4 oth | |
| 700 | 1 | |a Wang, Junyuan |4 oth | |
| 700 | 1 | |a Bahit, M. Cecilia |4 oth | |
| 700 | 1 | |a Verheugt, Freek |4 oth | |
| 700 | 1 | |a Lawrence, Jack |4 oth | |
| 700 | 1 | |a Xavier, Denis |4 oth | |
| 700 | 1 | |a Wallentin, Lars |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |t 625: Withdrawn |d 2013 |d AHJ |g Amsterdam [u.a.] |w (DE-627)ELV011791055 |
| 773 | 1 | 8 | |g volume:169 |g year:2015 |g number:1 |g pages:25-30 |g extent:6 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ahj.2014.09.006 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a FID-BIODIV | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 169 |j 2015 |e 1 |h 25-30 |g 6 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
c b g cb cbg |
|---|---|
| matchkey_str |
grangerchristopherblopesrenatodhannamich:2015----:lnclvnsfetastoigrmpxbnessafrnoafrnthedfhaiaafreutoisrkadtetrmom |
| hierarchy_sort_str |
2015 |
| publishDate |
2015 |
| allfields |
10.1016/j.ahj.2014.09.006 doi GBVA2015019000025.pica (DE-627)ELV023904658 (ELSEVIER)S0002-8703(14)00564-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 570 VZ BIODIV DE-30 fid Granger, Christopher B. verfasserin aut Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial 2015 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier We sought to assess the occurrence of events after blinded study drug discontinuation and transition to open-label vitamin K antagonist (VKA) in ARISTOTLE. Lopes, Renato D. oth Hanna, Michael oth Ansell, Jack oth Hylek, Elaine M. oth Alexander, John H. oth Thomas, Laine oth Wang, Junyuan oth Bahit, M. Cecilia oth Verheugt, Freek oth Lawrence, Jack oth Xavier, Denis oth Wallentin, Lars oth Enthalten in Elsevier 625: Withdrawn 2013 AHJ Amsterdam [u.a.] (DE-627)ELV011791055 volume:169 year:2015 number:1 pages:25-30 extent:6 https://doi.org/10.1016/j.ahj.2014.09.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA AR 169 2015 1 25-30 6 045F 610 |
| spelling |
10.1016/j.ahj.2014.09.006 doi GBVA2015019000025.pica (DE-627)ELV023904658 (ELSEVIER)S0002-8703(14)00564-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 570 VZ BIODIV DE-30 fid Granger, Christopher B. verfasserin aut Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial 2015 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier We sought to assess the occurrence of events after blinded study drug discontinuation and transition to open-label vitamin K antagonist (VKA) in ARISTOTLE. Lopes, Renato D. oth Hanna, Michael oth Ansell, Jack oth Hylek, Elaine M. oth Alexander, John H. oth Thomas, Laine oth Wang, Junyuan oth Bahit, M. Cecilia oth Verheugt, Freek oth Lawrence, Jack oth Xavier, Denis oth Wallentin, Lars oth Enthalten in Elsevier 625: Withdrawn 2013 AHJ Amsterdam [u.a.] (DE-627)ELV011791055 volume:169 year:2015 number:1 pages:25-30 extent:6 https://doi.org/10.1016/j.ahj.2014.09.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA AR 169 2015 1 25-30 6 045F 610 |
| allfields_unstemmed |
10.1016/j.ahj.2014.09.006 doi GBVA2015019000025.pica (DE-627)ELV023904658 (ELSEVIER)S0002-8703(14)00564-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 570 VZ BIODIV DE-30 fid Granger, Christopher B. verfasserin aut Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial 2015 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier We sought to assess the occurrence of events after blinded study drug discontinuation and transition to open-label vitamin K antagonist (VKA) in ARISTOTLE. Lopes, Renato D. oth Hanna, Michael oth Ansell, Jack oth Hylek, Elaine M. oth Alexander, John H. oth Thomas, Laine oth Wang, Junyuan oth Bahit, M. Cecilia oth Verheugt, Freek oth Lawrence, Jack oth Xavier, Denis oth Wallentin, Lars oth Enthalten in Elsevier 625: Withdrawn 2013 AHJ Amsterdam [u.a.] (DE-627)ELV011791055 volume:169 year:2015 number:1 pages:25-30 extent:6 https://doi.org/10.1016/j.ahj.2014.09.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA AR 169 2015 1 25-30 6 045F 610 |
| allfieldsGer |
10.1016/j.ahj.2014.09.006 doi GBVA2015019000025.pica (DE-627)ELV023904658 (ELSEVIER)S0002-8703(14)00564-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 570 VZ BIODIV DE-30 fid Granger, Christopher B. verfasserin aut Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial 2015 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier We sought to assess the occurrence of events after blinded study drug discontinuation and transition to open-label vitamin K antagonist (VKA) in ARISTOTLE. Lopes, Renato D. oth Hanna, Michael oth Ansell, Jack oth Hylek, Elaine M. oth Alexander, John H. oth Thomas, Laine oth Wang, Junyuan oth Bahit, M. Cecilia oth Verheugt, Freek oth Lawrence, Jack oth Xavier, Denis oth Wallentin, Lars oth Enthalten in Elsevier 625: Withdrawn 2013 AHJ Amsterdam [u.a.] (DE-627)ELV011791055 volume:169 year:2015 number:1 pages:25-30 extent:6 https://doi.org/10.1016/j.ahj.2014.09.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA AR 169 2015 1 25-30 6 045F 610 |
| allfieldsSound |
10.1016/j.ahj.2014.09.006 doi GBVA2015019000025.pica (DE-627)ELV023904658 (ELSEVIER)S0002-8703(14)00564-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 570 VZ BIODIV DE-30 fid Granger, Christopher B. verfasserin aut Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial 2015 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier We sought to assess the occurrence of events after blinded study drug discontinuation and transition to open-label vitamin K antagonist (VKA) in ARISTOTLE. Lopes, Renato D. oth Hanna, Michael oth Ansell, Jack oth Hylek, Elaine M. oth Alexander, John H. oth Thomas, Laine oth Wang, Junyuan oth Bahit, M. Cecilia oth Verheugt, Freek oth Lawrence, Jack oth Xavier, Denis oth Wallentin, Lars oth Enthalten in Elsevier 625: Withdrawn 2013 AHJ Amsterdam [u.a.] (DE-627)ELV011791055 volume:169 year:2015 number:1 pages:25-30 extent:6 https://doi.org/10.1016/j.ahj.2014.09.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA AR 169 2015 1 25-30 6 045F 610 |
| language |
English |
| source |
Enthalten in 625: Withdrawn Amsterdam [u.a.] volume:169 year:2015 number:1 pages:25-30 extent:6 |
| sourceStr |
Enthalten in 625: Withdrawn Amsterdam [u.a.] volume:169 year:2015 number:1 pages:25-30 extent:6 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
625: Withdrawn |
| authorswithroles_txt_mv |
Granger, Christopher B. @@aut@@ Lopes, Renato D. @@oth@@ Hanna, Michael @@oth@@ Ansell, Jack @@oth@@ Hylek, Elaine M. @@oth@@ Alexander, John H. @@oth@@ Thomas, Laine @@oth@@ Wang, Junyuan @@oth@@ Bahit, M. Cecilia @@oth@@ Verheugt, Freek @@oth@@ Lawrence, Jack @@oth@@ Xavier, Denis @@oth@@ Wallentin, Lars @@oth@@ |
| publishDateDaySort_date |
2015-01-01T00:00:00Z |
| hierarchy_top_id |
ELV011791055 |
| dewey-sort |
3610 |
| id |
ELV023904658 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV023904658</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623172015.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ahj.2014.09.006</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2015019000025.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV023904658</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0002-8703(14)00564-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Granger, Christopher B.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">We sought to assess the occurrence of events after blinded study drug discontinuation and transition to open-label vitamin K antagonist (VKA) in ARISTOTLE.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lopes, Renato D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hanna, Michael</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ansell, Jack</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hylek, Elaine M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Alexander, John H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Thomas, Laine</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wang, Junyuan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bahit, M. Cecilia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Verheugt, Freek</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lawrence, Jack</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xavier, Denis</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wallentin, Lars</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="t">625: Withdrawn</subfield><subfield code="d">2013</subfield><subfield code="d">AHJ</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV011791055</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:169</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:25-30</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ahj.2014.09.006</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">169</subfield><subfield code="j">2015</subfield><subfield code="e">1</subfield><subfield code="h">25-30</subfield><subfield code="g">6</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Granger, Christopher B. |
| spellingShingle |
Granger, Christopher B. ddc 610 ddc 570 fid BIODIV Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial |
| authorStr |
Granger, Christopher B. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV011791055 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 570 - Life sciences; biology |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 570 VZ BIODIV DE-30 fid Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial |
| topic |
ddc 610 ddc 570 fid BIODIV |
| topic_unstemmed |
ddc 610 ddc 570 fid BIODIV |
| topic_browse |
ddc 610 ddc 570 fid BIODIV |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
r d l rd rdl m h mh j a ja e m h em emh j h a jh jha l t lt j w jw m c b mc mcb f v fv j l jl d x dx l w lw |
| hierarchy_parent_title |
625: Withdrawn |
| hierarchy_parent_id |
ELV011791055 |
| dewey-tens |
610 - Medicine & health 570 - Life sciences; biology |
| hierarchy_top_title |
625: Withdrawn |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV011791055 |
| title |
Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial |
| ctrlnum |
(DE-627)ELV023904658 (ELSEVIER)S0002-8703(14)00564-X |
| title_full |
Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial |
| author_sort |
Granger, Christopher B. |
| journal |
625: Withdrawn |
| journalStr |
625: Withdrawn |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2015 |
| contenttype_str_mv |
zzz |
| container_start_page |
25 |
| author_browse |
Granger, Christopher B. |
| container_volume |
169 |
| physical |
6 |
| class |
610 610 DE-600 610 VZ 570 VZ BIODIV DE-30 fid |
| format_se |
Elektronische Aufsätze |
| author-letter |
Granger, Christopher B. |
| doi_str_mv |
10.1016/j.ahj.2014.09.006 |
| dewey-full |
610 570 |
| title_sort |
clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (aristotle) trial |
| title_auth |
Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial |
| abstract |
We sought to assess the occurrence of events after blinded study drug discontinuation and transition to open-label vitamin K antagonist (VKA) in ARISTOTLE. |
| abstractGer |
We sought to assess the occurrence of events after blinded study drug discontinuation and transition to open-label vitamin K antagonist (VKA) in ARISTOTLE. |
| abstract_unstemmed |
We sought to assess the occurrence of events after blinded study drug discontinuation and transition to open-label vitamin K antagonist (VKA) in ARISTOTLE. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA |
| container_issue |
1 |
| title_short |
Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial |
| url |
https://doi.org/10.1016/j.ahj.2014.09.006 |
| remote_bool |
true |
| author2 |
Lopes, Renato D. Hanna, Michael Ansell, Jack Hylek, Elaine M. Alexander, John H. Thomas, Laine Wang, Junyuan Bahit, M. Cecilia Verheugt, Freek Lawrence, Jack Xavier, Denis Wallentin, Lars |
| author2Str |
Lopes, Renato D. Hanna, Michael Ansell, Jack Hylek, Elaine M. Alexander, John H. Thomas, Laine Wang, Junyuan Bahit, M. Cecilia Verheugt, Freek Lawrence, Jack Xavier, Denis Wallentin, Lars |
| ppnlink |
ELV011791055 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.ahj.2014.09.006 |
| up_date |
2024-07-06T20:01:58.134Z |
| _version_ |
1803861222368477184 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV023904658</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623172015.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ahj.2014.09.006</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2015019000025.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV023904658</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0002-8703(14)00564-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Granger, Christopher B.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">We sought to assess the occurrence of events after blinded study drug discontinuation and transition to open-label vitamin K antagonist (VKA) in ARISTOTLE.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lopes, Renato D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hanna, Michael</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ansell, Jack</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hylek, Elaine M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Alexander, John H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Thomas, Laine</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wang, Junyuan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bahit, M. Cecilia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Verheugt, Freek</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lawrence, Jack</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xavier, Denis</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wallentin, Lars</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="t">625: Withdrawn</subfield><subfield code="d">2013</subfield><subfield code="d">AHJ</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV011791055</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:169</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:25-30</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ahj.2014.09.006</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">169</subfield><subfield code="j">2015</subfield><subfield code="e">1</subfield><subfield code="h">25-30</subfield><subfield code="g">6</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.399315 |